XURIDEN is an analog of the organic compound pyrimidine. Oral administration of XURIDEN delivers four to seven times more uridine than oral administration of uridine itself. The commercial launch will commence in early 2016.
Today, the U.S. Food and Drug Administration approved Xuriden (uridine triacetate), the first FDA-approved treatment for patients with hereditary orotic aciduria. Hereditary orotic aciduria is a rare metabolic disorder, which has been reported in approximately 20 patients worldwide.